. Physiological effects of glucocorticoids and the hypothalamus-pituitary-adrenal axis. CRF = corticotropin-releasing factor ; ACTH = adrenocorticotrophin hormone; (+) indicates stimulation and (-) indicates inhibition.
Synthetic glucocorticoids
Synthetic glucocorticoids are usually synthesized from cholic acid obtained from cattle or steroid sapogenins found in plants. The differs from cortisol only by a δ-1-dihydro configuration. Instead, bexamethasone and betamethasone have additional 9--fluoro and 16--or 16--methyl groups, respectively (Tegethoff et al. 2009 ). Endogenous and synthetic glucocorticoids regulate a number of physiological and behavioural responses via intracellular receptors, which modulate the function of neural cells. In several brain regions, neural cells express two types of corticoid receptors: Type-1 receptors, also called mineralocorticoid receptors (MRs), and Type-2 receptors, also called glucocorticoid receptors (GRs) or NR3C1 (nuclear receptor subfamily 3, group C, member 1) (Fietta et al. 2009; Hoppmann et al. 2010; Marques et al. 2009; Prager et al. 2010) . NR3C1 mediates the negative feedback in the HPA axis and in other limbic structures (de Kloet 2003; De Kloet et al. 1998) . GRs have tenfold lesser affinity for corticosteroids than MRs (Table 1) . The physiological outcome of these interactions is that GRs are mainly active during periods of abundant glucocorticoid secretion, such as circadian peak, systemic inflammation or stress. Thus, some of the functions of GRs include the regulation of energy metabolism, cellular homeostasis, stress-induced response, information storage and retrieval (de Kloet 2003; de Kloet et al. 1999; De Kloet et al. 1998) . In contrast, MRs have a high affinity for corticosteroids; as a result, they are active when circulating glucocorticoid levels are relatively low. These receptors are highly expressed in hippocampus, septum, amygdala, frontal cortex, hypothalamic paraventricular nucleus and locus coeruleus (de Kloet 2003; De Kloet et al. 1998) . One of the main functions of MRs is the regulation of basal HPA tone (de Kloet 2003; De Kloet et al. 1998 Table 2 . Potency and plasma half-life of natural and synthetic glucocorticoids commonly used in medicine.
The pharmacological effects of natural and synthetic glucocorticoids are mediated by the same genomic and non-genomic pathways (Buckingham 2006; Lowenberg et al. 2005; Lowenberg et al. 2006) . The levels of efficacy, potency and pharmacological activity of synthetic hormones are determined by their pharmacokinetic properties (Table 2) (Fietta et al. 2009; GonzalezPerez et al. 2007 ). In clinic, synthetic glucocorticoids are commonly used as anti-inflammatory drugs for the treatment of allergies, rheumatic diseases, asthma, lymphoproliferative diseases and autoimmune disorders (Liberman et al. 2010) . Most, if not all, of them can bind to both MRs and GRs, but with different affinities (Gonzalez-Perez et al. 2007) . Remarkably, an increasing number of pre-clinical and clinical studies indicate that synthetic glucocorticoids can modify the citoarchitecture and function of glial cells, which alter the brain homeostasis. 
Effects of synthetic glucocorticoids on astroglia
GRs and MRs are expressed not only by neurons, but also by glial cells or neuroglia (Bohn et al. 1991; Vielkind et al. 1990 ). Glial cells are non-neuronal cells that preserve neural homeostasis, form myelin, and provide support and protection for neurons. In fact, corticoids exert several effects into the brain by targeting glial cells that, in turn, modify the cerebral functioning (Figure 3) . Astrocytes, collectively known as astroglia, are the most abundant glial cells and play multiple roles into the brain, such as: Neurotransmitter reuptake and release, modulation of synaptic transmission, nervous system repair, hormonal signalling, vascular tone regulation, preservation of blood-brain barrier and, in some cases, astrocytes may function as neural stem cells (Gonzalez-Perez & Alvarez-Buylla 2011; Kettenmann & Ransom 2005) . Astroglia expresses the intermediate filament glial fibrilliary acidic protein (GFAP), which is used as cellular marker of these cells (Ihrie & Alvarez-Buylla 2008) . Interestingly, astrocytes contain high number of GRs and MRs; consequently, astrocyte function and their GFAP expression are highly susceptible to glucocorticoids (Lambert et al. 2000; Rozovsky et al. 1995) . Some of the effects of glucocorticoids on gene and protein expression in astrocytes are summarized in the In vitro administration of dexamethasone, corticosterone or aldosterone inhibits astrocyte proliferation in a dose-dependent manner (Crossin et al. 1997 ). This effect seems to be mediated by neural cell adhesion molecules, which inhibit activation of mitogen-activated protein (MAP) kinase (Krushel et al. 1998 ). The corticoid-induced inhibition of cell proliferation and growth retardation may also be enhanced by a concomitant reduction in the production of insulin-like growth factor 1 (IGF-1) in parenchymal astrocytes (Adamo et al. 1988 ). On the other hand, the overexpression of GFAP and chondroitin sulfate proteoglycans in reactive astrocytes has been related to a deficient neuronal repair and less neurite outgrowth. Methylprednisolone can revert these adverse effects by downregulating astrocyte activation (Liu et al. 2008 ) and reducing the number of GFAP-expressing astroglia (Sabolek et al. 2006) . Further studies indicate that dexamethasone can modify hippocampal neuron development and survival by decreasing the mRNA levels of nerve growth factor (NGF) (Niu et al. 1997 ) and GFAP in hippocampus and neocortex (Aleong et al. 2003) . In contrast, other reports using corticosterone (Bridges et al. 2008 ), prednisone (Ramos-Remus et al. 2002 and deflazacort (Gonzalez-Castaneda et al. 2007) reported an increase in the number and cytoplasmic processes of hippocampal and cortical astrocytes. The reason for these discrepancies is not well-known, but they appear to be mediated by dose-and regiondependent phenomena ( The glial glutamate transporter-1 (GLT-1) is also affected by synthetic glucocorticoids. In cortical astrocytes, dexamethasone provokes a marked increase in the GLT-1 transcription and GLT-1 protein levels (Zschocke et al. 2005) . GABAergic neurons are also affected by synthetic glucocorticoids that impair their rhythmic firing, which may lead to cognitive deficit (Hu et al. 2010) . Taken together, this evidence indicates that synthetic glucocorticoids exert a strong modulation on neural cells by modifying protein expression, neurite growth, cell proliferation, neurotransmitter uptake, neuronal firing, vasculature function and neuronal degeneration.
Implications in autoimmune neurological disorders. Pathological features observed in patients upon GCs administration
One major application of synthetic glucocorticoids is the treatment of acute and chronic neuroinflammatory disorders, such as multiple sclerosis, autoimmune encephalomyelitis, immune rejection, Parkinson's disease, retinal degeneration and others. Increasing evidence indicates that the therapeutic efficacy of glucocorticoids against autoimmune disorders may rely not only on their well-known anti-inflammatory effects, but also on their properties of neuro-gliomodulation (Gonzalez-Perez et al. 2007 ). For instance, methylprednisolone has a synergistic effect with Nogo-66 receptor protein, which promotes functional recovery and axonal growth in a model of spinal cord contusion (Ji et al. 2005) . Methylprednisolone also mediates anti-apoptotic effects on oligodendrocytes by activating STAT5 proteins, which up-regulate a splicing isoform of the bcl-x gene (Xu et al. 2009 ). On the other hand, prednisone contributes to attenuate experimental autoimmune encephalomyelitis by preventing the reduction of brain-derived neurotrophic factor (BDNF) and NGF mRNA expression into the brain ). Promising results have also been obtained with dexamethasone and fluocinolone in several studies, i.e. dexamethasone reduces astroglial reactivity to implanted neuroprosthetic devices in rat cortex (Spataro et al. 2005) , whereas intravitreous administration of fluocinolone attenuates retinal degeneration (Glybina et al. 2010) . Further evidence suggests that dexamethasone produces immunosuppressive effects on the astrocyte response to interleukin-1-beta stimulation (Pousset et al. 1999) and counteracts blood-brain barrier failure by decreasing transendothelial permeability (Cucullo et al. 2004) . Despite synthetic glucocorticoids have demonstrated an adequate safety profile, increasing clinical experience and experimental studies indicate that corticoids are able to promote cognitive dysfunction, anxiety, cerebral atrophy, depression and steroid psychosis. One of the first studies that associated the glucocorticoid delivery with mood disorders in humans was reported in prednisone-treated asthmatic children (Bender et al. 1991) . However, adults are also affected by corticoids as demonstrated in healthy volunteers that, after receiving a high-dose prednisone or dexamethasone, showed mood changes and memory impairment (Keenan et al. 1996; Schmidt et al. 1999; Wolkowitz 1994) . Cerebral atrophy was reported after a long-term treatment with glucocorticoids in patients with no previous history of central nervous system affection (Bentson et al. 1978; Hara et al. 1981) . Other immunologic disorders, such as systemic corticosteroid hypersensitivity (de Sousa et al. 2010; Rachid et al. 2011) , toxic epidermal necrolysis (Navarro Llanos et al. 1996) or urticaria-angioedema (Gomez et al. 2002) , have also been associated with the administration of glucocorticoids.
Under specific circumstances synthetic corticoids may impair or even potentiate the progress of neurological disorders as reported in experimental models of Alzheimer's disease, hypoxia or prenatal glucocorticoid delivery. This fact appears to be particularly important in neurodegenerative disorders related to oxysterol production such as Alzheimer's disease and multiple sclerosis. Oxysterols are oxidized forms of cholesterol that provokes oligodendrocyte apoptosis. Dexamethasone exacerbates the apoptotic effects of oxysterols on oligodendrocytes, resulting in secondary necrosis (Trousson et al. 2009 ). Cerebral vasculature is also altered by exposure to dexamethasone that may deteriorate hippocampal functions (Neigh et al. 2010) . In hypoxia models, dexamethasone increases the expression of Bnip3, a pro-apoptotic Bcl-2 family, which impairs hypoxic tissue damage (Sandau & Handa 2007) . Neuronal function and survival are also affected by synthetic corticoids. Dexamethasone increases oxidative stress and expression of monoamine oxidase A and B, resulting in a higher loss of dopaminergic neurons (Arguelles et al. 2010) . Oral administration of prednisone or deflazacort promotes neuronal degeneration of pyramidal neurons in CA1 and CA3 hippocampal regions (Gonzalez-Castaneda et al. 2007; Gonzalez-Perez et al. 2007; Ramos-Remus et al. 2002) . Dexamethasone also decreases the number of neurons in the striatum (dorsomedial caudate-putamen) and hippocampus (dentate gyrus, CA1 and CA3 subfields), which may account for some of the cognitive deficits seen following administration of glucocorticoids to healthy volunteers (Haynes et al. 2001) . Glucocorticoids also target the developing brain as reported in children exposed to synthetic glucocorticoids in uterus, who showed a reduction in fetal and, in some cases, newborn and infant HPA axis activity (Tegethoff et al. 2009 ). Other studies indicate that prenatal dexa-or betamethasone exposure also affects postnatal cognitive functions (Hauser et al. 2007; Hauser et al. 2006) , reduces the survival of cholinergic neurons (Emgard et al. 2007) , and produces permanent changes in the cytoarchitecture within midbrain dopamine nuclei (McArthur et al. 2005) .
Taken together, this evidence indicates that synthetic glucocorticoid may have detrimental effects on glial and neuronal integrity. Therefore, some authors have proposed that uncontrolled use of glucocorticoids may predispose to the development of a range of psychiatric and neurological conditions throughout life.
Conclusion
Synthetic glucocorticoids are a valuable therapeutic strategy against neuroinflammation and autoimmune disorders with neurological involvement. In fact, anti-inflammatory strategies receive growing attention for their potential to prevent pathological deterioration in multiple sclerosis (the most prevalent chronic autoimmune disease of the central nervous system), Parkinson's disease, autoimmune encephalomyelitis and other severe neurological disorders. Nevertheless, the uncontrolled use of glucocorticoids must be avoided because of their deleterious potential on cognition, neuronal survival and apoptosis induction. Yet, in those clinical situations where glucocorticoid use is necessary, a continuous neuropsychological assessment is strongly recommended to detect a possible neurological deterioration. 
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